News

NIH-led effort – including ISB – launches Big Data portal for Alzheimer’s drug discovery

The National Institutes of Health announced the launch of a new Alzheimer’s Big Data portal, which includes the first wave of data for use by the research community. This portal is the result of the Accelerating Medicines Partnership (AMP) program, which focuses on facilitating collaboration among government agencies, academia and industry in order to translate research more quickly to therapies.

The launch of the AMP Alzeheimers Disease Knowledge Portal is the first major release of the project, to which a consortium of teams contribute data and analysis: Eric Schadt, Ph.D., Icahn School of Medicine at Mount Sinai, New York; Philip De Jager, M.D., Ph.D., Eli and Edythe L. Broad Institute of MIT and Harvard, Boston; Todd Golde, M.D., Ph.D., University of Florida, Gainesville; and Alan Levey, M.D., Ph.D., Emory University, Atlanta. Researchers from Rush University, Chicago; Mayo Clinic, Jacksonville, Fla.; Institute for Systems Biology, Seattle; the University of California, Los Angeles and a number of other academic centers are also participating. ISB’s Price Lab is participating in this project through a collaboration with the University of Florida.

Ben Heavner, a research scientist in the Price Lab, is leading the bioinformatics work, which involves translating raw data into a uniform format and then uploading to the data portal. “This is a huge step for open science,” Ben said. “This portal offers access to thousands of data sets pre-publication so that all researchers have the opportunity to make the discoveries that will lead to better therapeutics .”

Read more about the NIH’s $45M in grants to support Alzheimer’s research.

Recent Articles

  • The Aging Microbiome

    Gut Microbiome Implicated in Healthy Aging and Longevity

    The gut microbiome is an integral component of the body, but its importance in the human aging process is unclear. ISB researchers and their collaborators have identified distinct signatures in the gut microbiome that are associated with either healthy or unhealthy aging trajectories, which in turn predict survival in a population of older individuals.

  • Drs. Anthony Fauci, Lee Hood Talk COVID-19, Vaccines, Future of Research, More

    NIAID Director Dr. Anthony Fauci sat down for a conversation with ISB’s Dr. Lee Hood. The renowned scientists spoke about the importance of basic research, the extraordinary speed of COVID research, the efficacy of mRNA vaccines on COVID-19, lessons learned from the COVID-19 pandemic, and much more.

  • Priyanka Baloni

    Bile Acids Provide More Evidence of the Gut Microbiome’s Effect on Alzheimer’s Disease

    ISB researchers and their collaborators are looking beyond the one-drug, one-solution approach that has thus far failed in Alzheimer’s disease research. Instead, they are focusing on other promising research avenues, such as the possible role of the gut microbiome in dementia.